Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficacy (AMBER)

X
Trial Profile

A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficacy (AMBER)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patiromer (Primary) ; Spironolactone
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Acronyms AMBER
  • Sponsors Relypsa
  • Most Recent Events

    • 14 Apr 2021 Results assessing the prespecified subgroups by sex, biological differences between men and women contribute to variations in drug response, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.
    • 03 Mar 2021 According to a Vifor media release, European Medicines Agency approved important changes to the label in December which included data from the phase-II AMBER clinical study.
    • 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top